Senseonics Stock Price, News & Analysis

Senseonics Holdings, Inc. (AMEX: SENS) has announced participation in two upcoming investor conferences. Management will engage in a virtual fireside chat on November 16, 2021, at 8:40am ET during the Stifel 2021 Virtual Healthcare Conference. Additionally, a presentation will be available on November 18, 2021, at 3:00am ET at the Jefferies London Healthcare Conference. Interested parties can access live and on-demand webcasts on the Company’s website. Senseonics focuses on long-term glucose monitoring systems for diabetes management.

Senseonics Holdings, Inc. (AMEX: SENS) has announced plans to release its third quarter 2021 financial results on November 9, 2021, after market close. A conference call will be held at 4:30 p.m. Eastern Time to discuss the company's performance for the quarter. Investors can access the webcast through Senseonics' website. The company specializes in developing long-term, implantable continuous glucose monitoring systems aimed at improving diabetes management.

Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to 11 new non-executive employees as of October 1, 2021. A total of 74,000 non-qualified stock options were granted at an exercise price of $3.45 per share, the closing price on the grant date. The options vest 25% on the first anniversary of employment, with the remainder vesting monthly over three years, dependent on continued service. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management.

The University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio, has commenced offering the Eversense® Continuous Glucose Monitoring (CGM) System to Medicare enrollees as of early September 2021. This initiative aims to improve diabetes management among patients with type 1 and type 2 diabetes who are on insulin. The Eversense CGM System, which features a long-term implantable sensor and a smart transmitter, enhances patient experience and supports better health outcomes, as emphasized by Betul Hatipoglu, M.D. at UHACO.

Senseonics Holdings, Inc. (NYSE American: SENS), specializing in long-term, implantable continuous glucose monitoring systems, plans to participate in the virtual H.C. Wainwright Global Investment Conference. Management will engage in one-on-one meetings on September 15, 2021, with a presentation webcast available starting September 13, 2021, at 7:00 AM ET. Access to the on-demand webcast will be provided on the company’s website. Senseonics is dedicated to transforming diabetes management with its Eversense® CGM products, which offer real-time glucose data via a mobile app.

Senseonics Holdings reported second quarter 2021 revenue of $3.3 million, significantly up from $0.26 million in Q2 2020. U.S. revenue was $0.98 million, while international revenue reached $2.31 million. The company raised $50 million through an equity offering, mainly for debt service. However, net loss expanded to $180.32 million or $0.42 per share, largely due to increased accounting charges. Senseonics projects 2021 global net revenue between $12 million to $15 million.

Senseonics Holdings, Inc. (NYSE-American: SENS) has announced its plan to release second quarter 2021 financial results on August 9, 2021, after market close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss its performance, with a concurrent webcast available on their website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, such as the Eversense and Eversense XL, which provide real-time glucose data to users via a smartphone app.

Senseonics Holdings has granted equity to new employees as per its 2019 Inducement Plan. On July 1, 2021, the Compensation Committee approved 66,000 non-qualified stock options for five new non-executive employees, with an exercise price of $3.50 per share. The vesting schedule includes 25% on the first anniversary of their start date and the rest monthly over three years, contingent on continued service. The company aims to expand its Eversense continuous glucose monitoring (CGM) system for diabetes management.

Senseonics Holdings, Inc. (NYSE American: SENS) presented new data from the PROMISE Study regarding its Eversense CGM System at the American Diabetes Association’s 81st Annual Scientific Sessions. The findings indicate that the next-generation device demonstrates safety and accuracy comparable to the current 90-day sensor with extended usage up to 180 days. Key metrics include a mean absolute relative difference (MARD) of 9.1% and high hypoglycemia alert detection rates. The Eversense system enhances user experience by offering discreet alerts and a rechargeable transmitter.